• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hepatitis A - Pipeline Review, Q4 2010 - Product Image

Hepatitis A - Pipeline Review, Q4 2010

  • Published: December 2010
  • 31 pages
  • Global Markets Direct

Hepatitis A - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Hepatitis A Infection Pipeline Review, Q4 2010”, provides an overview of the Hepatitis A Infection therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis A Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis A Infection. “Hepatitis A Infection-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis A Infection.
- A review of the Hepatitis A Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis A Overview
Therapeutics Development
An Overview of Pipeline Products for Hepatitis A
Hepatitis A Therapeutics under Development by Companies
Hepatitis A Therapeutics under Investigation by Universities/Institutes
Companies Involved in Hepatitis A Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
Variation Biotechnologies, Inc.
Universities/Institutes Involved in Hepatitis A Therapeutics Development
Hepatitis A Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Havrix + Infanrix + ActHIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Havrix + M-M-RII + Varivax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaqta + Infanrix + PedvaxHIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaqta + PedvaxHIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Hepatitis A vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos